These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33969823)

  • 21. Polycythemia following allogeneic hematopoietic progenitor cell transplantation occurring during iron chelation therapy.
    Fedele R; Cuzzola M; Irrera G; Pontari A; D'Ascola DG; Oliva EN; Martino M
    Leuk Lymphoma; 2016; 57(4):969-72. PubMed ID: 26308385
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy and Safety of Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Thalassemia Patients: A Retrospective Observational Study.
    Kupesiz FT; Sivrice C; Akinel A; Kintrup GT; Guler E; Kupesiz A
    J Pediatr Hematol Oncol; 2022 Jan; 44(1):e26-e34. PubMed ID: 34986131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Impacts of iron overload on hematopoiesis and its microenvironment].
    Suzuki T
    Rinsho Ketsueki; 2015 Jun; 56(6):577-85. PubMed ID: 26256865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of iron overload on poor graft function after allo-HSCT in a patient with transfusion-dependent low-risk MDS: A case report and literature review.
    Wang C; Zhao M; Nie Y; Yang Y; Tan Y; Du Z; Gao S; Li W
    Medicine (Baltimore); 2022 Dec; 101(51):e32012. PubMed ID: 36595778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iron overload: predictor of adverse outcome in hematopoietic stem cell transplantation.
    Sucak GT; Yegin ZA; Ozkurt ZN; Aki SZ; Yağci M
    Transplant Proc; 2010 Jun; 42(5):1841-8. PubMed ID: 20620535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload.
    Sivgin S; Baldane S; Akyol G; Keklik M; Kaynar L; Kurnaz F; Pala C; Zararsiz G; Cetin M; Eser B; Unal A
    Transfus Apher Sci; 2013 Oct; 49(2):295-301. PubMed ID: 23916904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies.
    Kim YR; Kim JS; Cheong JW; Song JW; Min YH
    Acta Haematol; 2008; 120(3):182-9. PubMed ID: 19129689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iron overload in the HCT patient: a review.
    Tenneti P; Chojecki A; Knovich MA
    Bone Marrow Transplant; 2021 Aug; 56(8):1794-1804. PubMed ID: 33782548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.
    Leitch HA
    Drugs; 2011 Jan; 71(2):155-77. PubMed ID: 21275444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iron overload and its impact on outcome of patients with hematological diseases.
    Franke GN; Kubasch AS; Cross M; Vucinic V; Platzbecker U
    Mol Aspects Med; 2020 Oct; 75():100868. PubMed ID: 32620237
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Iron overload as a risk factor for poor graft function following allogeneic hematopoietic stem cell transplantation.
    Wu XQ; Lin KN; Chen MM; Jiang PF; Zhang YX; Chen YQ; Chen QR; Xiao M; Zhu HJ; Issa HA; Chen SZ; Luo XF; Ren JH; Li Q; Zeng YL; Xu JJ; Lin YF; Zheng R; Zheng ZH; Chen ZZ; Hu JD; Yang T
    Kaohsiung J Med Sci; 2020 Oct; 36(10):825-833. PubMed ID: 32729195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of labile plasma iron in patients who undergo hematopoietic stem cell transplantation.
    Naoum FA; Espósito BP; Ruiz LP; Ruiz MA; Tanaka PY; Sobreira JT; Cançado RD; de Barros JC
    Acta Haematol; 2014; 131(4):222-6. PubMed ID: 24335268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cotransplantation of Umbilical Cord Mesenchymal Stem Cells Promotes the Engraftment of Umbilical Cord Blood Stem Cells in Iron Overload NOD/SCID Mice.
    Huang Z; Xiao Y; Chen X; Li H; Gao J; Wei W; Zhang X; Feng X
    Transplant Cell Ther; 2021 Mar; 27(3):230.e1-230.e7. PubMed ID: 35348116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes.
    Angelucci E; Cianciulli P; Finelli C; Mecucci C; Voso MT; Tura S
    Leuk Res; 2017 Nov; 62():108-115. PubMed ID: 29054020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions.
    Leitch HA; Gattermann N
    Crit Rev Oncol Hematol; 2019 Sep; 141():54-72. PubMed ID: 31228649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum ferritin is not a reliable predictor to determine iron overload in thalassemia major patients post-hematopoietic stem cell transplantation.
    Jarisch A; Salzmann-Manrique E; Cario H; Grosse R; Soerensen J; Fischer R; Schulz A; Hammerstingl R; Wunderlich A; Bader P
    Eur J Haematol; 2018 Dec; 101(6):791-797. PubMed ID: 30187571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase II, Multicenter, Single-Arm Study to Evaluate the Safety and Efficacy of Deferasirox after Hematopoietic Stem Cell Transplantation in Children with β-Thalassemia Major.
    Yesilipek MA; Karasu G; Kaya Z; Kuskonmaz BB; Uygun V; Dag I; Ozudogru O; Ertem M
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):613-618. PubMed ID: 29155313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of mesenchymal stem cells co-infusion in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis.
    Li T; Luo C; Zhang J; Wei L; Sun W; Xie Q; Liu Y; Zhao Y; Xu S; Wang L
    Stem Cell Res Ther; 2021 Apr; 12(1):246. PubMed ID: 33879242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Iron overload and allogeneic hematopoietic stem-cell transplantation.
    Kanda J; Kawabata H; Chao NJ
    Expert Rev Hematol; 2011 Feb; 4(1):71-80. PubMed ID: 21322780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Fortin PM; Fisher SA; Madgwick KV; Trivella M; Hopewell S; Doree C; Estcourt LJ
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012349. PubMed ID: 29737522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.